Guggenheim Remains Arcellx (ACLX) Purchase Recommendation
Fintel announced on April 24, 2023, the Guggenheim maintained Arcellx (NASDAQ:ACLX) Coverage buy recommendation.
Analyst price forecasts suggest a 1.16% gain
Average 1 year as of April 24, 2023 price target For Arcellx it is 40.69. Predictions range from a low of $35.35 to a high of $47.25. The average price target represents an increase of 1.16% from the latest reported closing price of 40.22.
see us corporate leaderboard Maximum price target upwards.
Arcellx’s projected annual revenue is 0MM. Projected Annual Non-GAAP EPS -4.11.
What is Fund Sentiment?
there is 261 funds or institutions reporting positions at Arsel. This is he 78 owners or an increase of 42.62% in the previous quarter.Portfolio average weight of all funds ACLX dedicated was 0.69%, a decrease of 9.27%. The total number of shares owned by the institution increased by 5.59% to 45,500K shares over the past three months. of put/call ratio of ACLX is 0.14, indicating a bullish outlook.
What are other shareholders doing?
Senior One Capital Management It holds 5,500,000 shares representing an 11.50% ownership interest in the company. No change from the previous quarter.
NEA management company It owns 4,745,000 shares representing a 9.92% ownership interest in the company. In previous filings, the company reported that it owned 6,750,000 of his shares. Decrease 42.25%.office gain Portfolio allocation at ACLX increased 30.63% last quarter.
Perception Advisor It owns 2,598,000 shares representing a 5.43% ownership interest in the company. In previous filings, the company reported he owned 2,465,000 shares. will increase 5.11%.office gain Portfolio allocation at ACLX increased 68.30% last quarter.
Subletta Capital Management It owns 2,350,000 shares representing a 4.91% ownership interest in the company. In previous filings, the company reported he owned 2,250,000 shares. will increase 4.29%.office gain Portfolio allocation on ACLX increased 74.42% last quarter.
Asset management of cormorants It holds 2,075,000 shares representing a 4.34% ownership interest in the company. In previous filings, the company reported that it owned 3,049,000 of his shares. Decrease 46.95%.office gain Portfolio allocation at ACLX increased 7.53% last quarter.
Acerx Background Information
(This description is provided by the company.)
Arcellx Inc. is a clinical-stage biotechnology company. The company is focused on developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.
view all Submissions to regulatory authorities.
This story was originally Fintel.
The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.
Summarize this content to 100 words
Fintel announced on April 24, 2023, the Guggenheim maintained Arcellx (NASDAQ:ACLX) Coverage buy recommendation. Analyst price forecasts suggest a 1.16% gain Average 1 year as of April 24, 2023 price target For Arcellx it is 40.69. Predictions range from a low of $35.35 to a high of $47.25. The average price target represents an increase of 1.16% from the latest reported closing price of 40.22.
see us corporate leaderboard Maximum price target upwards. Arcellx’s projected annual revenue is 0MM. Projected Annual Non-GAAP EPS -4.11. What is Fund Sentiment? there is 261 funds or institutions reporting positions at Arsel. This is he 78 owners or an increase of 42.62% in the previous quarter.Portfolio average weight of all funds ACLX dedicated was 0.69%, a decrease of 9.27%. The total number of shares owned by the institution increased by 5.59% to 45,500K shares over the past three months. of put/call ratio of ACLX is 0.14, indicating a bullish outlook. What are other shareholders doing? Senior One Capital Management It holds 5,500,000 shares representing an 11.50% ownership interest in the company. No change from the previous quarter. NEA management company It owns 4,745,000 shares representing a 9.92% ownership interest in the company. In previous filings, the company reported that it owned 6,750,000 of his shares. Decrease 42.25%.office gain Portfolio allocation at ACLX increased 30.63% last quarter.
Perception Advisor It owns 2,598,000 shares representing a 5.43% ownership interest in the company. In previous filings, the company reported he owned 2,465,000 shares. will increase 5.11%.office gain Portfolio allocation at ACLX increased 68.30% last quarter. Subletta Capital Management It owns 2,350,000 shares representing a 4.91% ownership interest in the company. In previous filings, the company reported he owned 2,250,000 shares. will increase 4.29%.office gain Portfolio allocation on ACLX increased 74.42% last quarter. Asset management of cormorants It holds 2,075,000 shares representing a 4.34% ownership interest in the company. In previous filings, the company reported that it owned 3,049,000 of his shares. Decrease 46.95%.office gain Portfolio allocation at ACLX increased 7.53% last quarter. Acerx Background Information(This description is provided by the company.)
Arcellx Inc. is a clinical-stage biotechnology company. The company is focused on developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.
view all Submissions to regulatory authorities. This story was originally Fintel.
The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.
https://www.nasdaq.com/articles/guggenheim-maintains-arcellx-aclx-buy-recommendation Guggenheim Remains Arcellx (ACLX) Purchase Recommendation